JOHNSON & JOHNSON
CIK 0000200406 · NEW BRUNSWICK, NJ · Quarter end: 2026-06-30 · Filed on: 2026-08-06 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$798.7M
2026 Q2
Positions
15
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
98.4%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
PTGX
PROTAGONIST THERAPEUTICS INC
37.6%
NBTX
NANOBIOTIX
26.5%
MGTX
MEIRAGTX HLDGS PLC
11.2%
RAPP
RAPPORT THERAPEUTICS INC
9.3%
CTNM
CONTINEUM THERAPEUTICS INC
4.1%
LEGN
LEGEND BIOTECH CORP
2.9%
CVRX
CVRX INC
2.6%
XNCR
XENCOR INC
1.5%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.